ValuentumAd

Official PayPal Seal

Vertex Raises Bottom End of 2025 Revenue Guidance Range

publication date: May 6, 2025
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Source: Vertex Pharma. 

Vertex’s reported results were impacted by an intangible asset impairment charge of $379 million associated with VX-264, but the company’s non-GAAP net income still fell to $1.1 billion in the first quarter compared to $1.2 billion in last year’s quarter as a result of higher operating expenses. Looking to the balance of 2025, however, Vertex raised the low end of its revenue guidance range to be between $11.85-$12 billion, up from $11.75-$12 billion previously. The company ended the quarter with $11.4 billion in cash and cash equivalents and no traditional debt. Though Vertex’s first quarter results came in lower than expected, we continue to like the long term story at the company, particularly in pain management, and the stock remains key biotech exposure in the Best Ideas Newsletter portfolio.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.